RNS Number:8427R
Enterprise Venture Capital TrustPLC
07 November 2003


Chairman's Statement


Results and Review of Business

The six months to 30th September brought a general improvement in UK equity
markets. The increase in AIM values (approximately 18%) was particularly helpful
to Enterprise shareholders and I am delighted to report that, on advice from
Noble Fund Managers, our AIM portfolio significantly outperformed the market and
increased in value by 66%. We do, of course, have a heavy weighting in unquoted
companies but, nonetheless, the total capital value of our portfolio rose by 13%
during the six month period and we are able to report realised and unrealised
gains during the period of almost #1m.


We took advantage of early redemptions in our loan portfolio to accelerate the
return of funds to the holders of O shares. Half the asset value was returned to
O shareholders by way of a 35p per share dividend, which was paid in June.
Inevitably, this resulted in significantly lower income from interest earnings
during the six months to 30 September 2003.


It continues to be our intention to return the remainder of the funds
attributable to O shareholders in April 2004, shortly after the year end. Future
dividends to A shareholders will depend, as is the case with most other VCTs, on
the generation and realisation of capital gains.


Since April this year, shareholders have invested over #500,000 in acquiring new
A shares. This demonstration of confidence in the potential within our equity
portfolio is very pleasing and it is our intention to give O shareholders a
further opportunity to reinvest in A shares when we return the remainder of the
O Share capital in the Spring.


Investment Valuations

On 1st August 2003, the revised guidelines for valuing equity investments, drawn
up by the British Venture Capital Association (BVCA), took effect. After careful
consideration, and consultation with the Company's auditors, the Board decided
to adopt these guidelines as the basis for valuing the unquoted portfolio. With
regard to quoted investments, the Board decided to continue to value quoted
stocks at mid-market price in accordance with UK Generally Accepted Accounting
Practice.


Outlook

The flow of investment opportunities has remained strong and with the
improvement in values in quoted markets, it is unsurprising that, recently,
these have been concentrated in the AIM sector. We continue to be selective in
our choice of investments but we have the cash resources to take advantage when
attractive opportunities arise.


It is anticipated that, if the recent recovery in quoted markets is maintained,
benefits will flow through into the unquoted sector. Enterprise has an interest
in a number of established unquoted businesses which make it well placed to take
advantage of any sustained improvement in capital values. It was encouraging to
see that, in the recently published list of The Times 100 fastest growing
technology businesses, both Optos and Voxar were in the top 20. Indeed Optos was
at number 1.


Much depends on the general economic situation and, if recent trends continue,
the prospects for the Company are encouraging and we should continue, over time,
to be able to realise acceptable profits on our investments.


Patrick Lawrence

Chairman

7th November 2003



Statement of Total Return
(incorporating the Revenue Account*) of the Company
for the six months ended 30th September 2003

                    -------------                   -------------                   ------------
                    Six months ended               Six months ended                   Year ended
                  30th September 2003             30th September 2002               31st March 2003
                      (unaudited)                     (unaudited)                       (audited)
                   ---------------                ----------------                 ---------------
               -------    -------    ------    -------    -------    -------    ------    -------    -------
               Revenue    Capital    Total    Revenue    Capital     Total    Revenue    Capital     Total
                  #000       #000     #000       #000       #000      #000       #000       #000      #000
               -------     ------   ------    -------    -------    ------    -------     ------    ------

Gains/             
(losses) on
investments          -        981      981          -     (1,104)   (1,104)         -     (2,006)   (2,006)
Income             237          -      237        445          -       445        778          -       778
Investment        
management
fees              (127)         -     (127)      (139)         -      (139)      (264)         -      (264)
Other             
Expenses          (182)         -     (182)      (125)         -      (125)      (300)         -      (300)
                 -------     ------   ------    -------    -------    ------    -------     ------    ------


Return on          
ordinary
activities
before tax         (72)       981      909        181     (1,104)     (923)       214     (2,006)   (1,792)

Tax on              
ordinary        
activities          14          -       14        (45)         -       (45)       (37)         -       (37)
                 -------     ------   ------    -------    -------    ------    -------     ------    ------

Return on          
ordinary
activities
after tax          (58)       981      923        136     (1,104)     (968)       177     (2,006)   (1,829)

Dividends       
paid or         
proposed         (8,293)         -   (8,293)         -          -         -       (474)         -      (474)
                 -------     ------   ------    -------    -------    ------    -------     ------    ------

Transfer        
(from)/to       (8,351)       981   (7,370)       136     (1,104)     (968)      (297)    (2,006)   (2,303)
reserves         
                -------     ------   ------    -------    -------    ------    -------     ------    ------


Return per share

Basic per O       
Share             0.14p     (0.01)p   0.13p      0.47p     (0.03)p    0.44p      0.89p     (0.05)p    0.84p


Basic per A      
Share           (0.57)p     6.16p    5.59p      0.15p     (7.01)p   (6.86)p    (0.22)p   (12.73)p  (12.95)p


* The revenue column of this statement is the profit and loss account of the
Company.


Notes

1. Earnings for the first six months should not be taken as a guide to
the results for the full year.

2. The financial information contained in this report has been prepared
on the basis of the accounting policies adopted by the Company.

3. All revenue and capital items in the above statement derive from
continuing operations.

4. Unquoted investments have been valued in accordance with BVCA
guidelines. Quoted investments and investments traded on AIM are stated at
middle market price as at close of play on 30th September 2003 in accordance
with Generally Accepted Accounting Practice.

5. Basic revenue return per O Share and A Share is based on the net
revenue on ordinary activities after taxation. For the six months ended 30th
September 2003 this return is based on 23,693,369 O Shares and 15,956,947 A
Shares (30th September 2002: 23,693,369 O Shares and 15,650,473 A Shares), being
the weighted number of shares in issue during the period.

6. The net asset value per share for both the O Shares and the A Shares
has been calculated on the appropriate split allocation of the Company's assets
and liabilities.

7. The financial information for the six months ended 30th September
2003 and 30th September 2002 has not been audited and does not comprise full
financial statements within the meaning of Section 240 of the Companies Act
1985. The financial information for the year ended 31st March 2003 has been
abridged from the full Company financial statements for that year and those
statements have been filed with the Registrar of Companies. The auditors have
reported on those financial statements and that report was unqualified and did
not contain a statement under Section 237(2) of the Companies Act 1985.

8. Copies of the interim report have been mailed to shareholders and are
available from the Company Secretary and the registered office of the Company.


Balance Sheet
as at 30th September 2003

                                         ---------      ---------      ---------
                                     30th September 30th September  31st March
                                              2003           2002         2003
                                       (unaudited)     (unaudited)    (audited)
                                         ---------      ---------      --------- 
                                             #000           #000         #000
                                          ---------      ---------    ---------

Fixed assets
Investments                                14,539         18,377       17,195
Monies pending investment                   8,257         11,954       12,336
                                          ---------      ---------    ---------
                                           22,796         30,331       29,531
Current assets
Debtors                                        14            127           80
Cash at bank                                    -            252            -
                                          ---------      ---------    ---------
                                               14            379           80

Creditors: amounts falling due               
within one year                              (405)          (219)        (369)
                                           ---------      ---------    ---------

Net current (liabilities)/assets             (391)           160         (289)
                                           ---------      ---------    ---------
Net assets                                 22,405         30,491       29,242
                                           ---------      ---------    ---------

Capital and reserves
Called up share capital                     3,999          3,932        3,941
Capital redemption reserve                     41             27           30
Share premium account                         532         25,443       25,534
Special reserve                            30,236          4,789        4,772
Capital reserves (realised)                   396            260          300
Capital reserves (unrealised)              (4,194)        (4,139)      (5,081)
Revenue reserves                           (8,605)           179         (254)
                                          ---------      ---------    ---------
Equity Shareholders' Funds                 22,405         30,491       29,242
                                          ---------      ---------    ---------

Net asset value per O Share                 34.10p         70.57p       68.96p
Net asset value per A Share                 87.76p         88.14p       82.11p



Reconciliation of movements inshareholders' funds  

                                         ---------      ---------    ---------
                                                O              A
                                           Shares         Shares       Total
                                         ---------      ---------     ---------

Total net assets attributable at 1st       
April 2003                                 16,339         12,903       29,242
Purchase of own shares                          -            (69)         (69)
Capital subscribed                              -            636          636
Expenses of issue                               -            (34)         (34)
Total recognised gains and losses             
for the period                                 34            889          923
Dividends appropriated in the              
period                                     (8,293)             -       (8,293)
                                          ---------      ---------    ---------
Total net assets attributable at           
30th September 2003                        8,080         14,325       22,405
                                          ---------      ---------    ---------




Cash Flow Statement
for the six months ended 30th September 2003

                         ----------           -----------          -----------
                       Six months ended      Six months ended      Year ended
                        30th September        30th September        31st March
                       2003 (unaudited)      2002 (unaudited)     2003(audited)
                                         
                        ------------          ------------        ----------
                            
                     ------    ------     ------    ------      ------   ------
                     #000       #000       #000     #000         #000    #000
                     ------     ------    -------   -------      -----   ------
Operating activities

Investment income     
received -
qualifying            187                   354                  706

Deposit and            
similar interest
received - non
qualifying             98                   194                  201

Interest purchased    
with investments        -                   (42)                 (42)

Recovery of             
interest purchased
with investments        -                     -                   42

Investment           
management fees
paid                 (119)                 (141)                (193)

Secretarial fees      
paid                  (38)                  (33)                (128)

Other cash           (155)                 (166)                (244)
payments             

                    ------     ------    -------     -------  -------   -------
Net cash (outflow)
/inflow from
operating                        
activities                        (27)                   166                342

Taxation
UK corporation tax                
received                            -                      -                (67)

Financial investment

Sale of fixed       
income              1,466                 6,000                6,000

investments
Sale of qualifying  
loans               2,742                 1,000                2,300

Sale of AIM and      
other quoted
investments           533                     -                   99

Purchase of fixed       
income investments    -                  (1,015)                  -

Purchase of
unquoted
investments
and investments    (1,105)                 (830)              (3,035)
quoted on AIM  
                    ------     ------    -------     -------  -------   -------

Net cash inflow                3,636                  5,155              5,364
from financial
investment

Equity dividends paid
Dividends paid                (8,293)                  (355)              (830)
                    ------     ------    -------     -------  -------   -------
Net cash (outflow)
/inflow before
use of liquid                 (4,684)                 4,966              4,809
resources and
financing

Management of
liquid resources
Movement in                    4,080                 (5,084)            (5,466)
deposits

Financing
New share issue       636                     -                  108
Repurchase of own     
shares                (69)                  (27)                 (43)
Share issue           (34)                    -                   (6)
Net cash inflow/                 
(outflow) from       
financing                        533                    (27)                59
                    ------     ------    -------     -------  -------   -------
Decrease in cash                 (71)                  (145)              (598)
                    ------     ------    -------     -------  -------   -------


Prior to 30th September 2003, the Company held gilts and bonds primarily as
investments and not as liquid resources. Accordingly, movements in the holdings
of these investments are shown within "Financial investment" rather than within
"Management of liquid resources". As at 30th September 2003 the Company held no
such investment.


Summary of Investments
as at 30th September 2003

                                            Cost    Valuation    Valuation as %
A Share Fund                                #000         #000     of portfolio
-------------                           --------     --------          -------

Unquoted
Citel Technologies Limited (Nottingham)      691          345              3.9
Diagnology Limited (Belfast)                 530            -                -
DNA Research Innovations Limited (Kent)      400          400              4.5
e:gosystems.com plc (Nottingham)             200            -                -
DSM Geodata Limited (West Lothian)           350            -                -
Global Money Transfers Holdings Limited      500            -                -
(Liverpool)
Heritage Image Partnership Limited           500          125              1.4
(London)
iBase Image Systems Limited (Ilkley)         300           85              1.0
Integrated Environmental Solutions           325            -                -
Limited (Glasgow)
Internet pro-video Limited (Cambridge)       494            -                -
knowledge = power Limited (London)           250            -                -
Meridian Technique Limited (Basingstoke)     500          500              5.7
Optos plc (Dunfermline)                      500          477              5.4
Procession plc (Buckinghamshire)             500            -                -
Sirus Pharmaceuticals Limited                500          225              2.5
(Cambridge)
The Message Pad Limited (Warwick)          1,225        1,818             20.6
Voxar Limited (Edinburgh)                    875          875              9.9
Xention Discovery Limited (Cambridge)        175          175              2.0
YAbA Limited (Edinburgh)                     300            -                -

Quoted
Avionic Services plc (Surrey)                330          183              2.1
ComputerLand UK plc (Nottingham)             100          176              2.0
CRC Group plc (Thame)                        138          150              1.7
Deltex Medical Holdings plc (Chichester)     415           30              0.3
GX Networks plc (London)                     320          220              2.5
i-documentsystems group plc (London)          78           72              0.8
ID Data plc (Northamptonshire)               300          387              4.4
Maelor plc (Wrexham)                         288          292              3.3
Medical House (The) plc (Sheffield)          200          175              2.0
Murgitroyd Group plc (Glasgow)               200          223              2.5
Neutec Pharma plc (Manchester)               188          172              2.0
Online Travel Corporation plc                200          262              3.0
(Twickenham)
Osmetech plc (Crewe)                         100          159              1.8
Pharmagene plc (Royston)                     486          581              6.6
VI Group plc (Gloucestershire)               400          193              2.2
Zoo Digital Group plc (Sheffield)            160          524              5.9
                                         --------     --------          -------

Total A Share Fund Investments            13,018        8,824            100.0
                                         --------     --------          -------

O Share Fund (Qualifying loans)
Total O Share Fund Investments             5,715        5,715            100.0
                                          --------     --------          -------

Total Investments                         18,733       14,539
                                          --------     --------          -------





Top Ten Equity Investments

1. The Message Pad Limited (20.6%)
The provision of contact management services to companies requiring
personal telephone response, particularly in respect of sales or technical
support activities, media response and those requiring an
out of hours response service.

2. Voxar Limited (9.9%)
Voxar has developed a software package which represents information in
3 dimensions using low powered computers. Data from medical scanners is fed into
the software tool and a 3D image is displayed. This can be manipulated so that
different layers of information can be extracted and viewed. It has particular
application in the medical field.

3.  Pharmagene plc (6.6%)
Human biomaterials analysis for medical research. Pharmagene has a
database of human biomaterials and the effect that a variety of drugs has on
these body parts. Customers buy the information and also buy access to test
their drugs on the body parts.

4. Zoo Digital Group plc (5.9%)
Zoo Digital Group plc are a growing DVD technology and videogame
publishing company. The company has developed a system called 'DVD-Extra' to
take interactive products to the DVD-video platform. A recent launch on
DVD-Extra was an interactive version of Who Wants To Be A Millionaire?

5. Meridian Technique Limited (5.7%)
Meridian Technique Limited has developed an Orthopaedic digital
templating software called Orthoview. Orthoview, which was recently granted FDA
approval in the USA, is being used worldwide and allows surgeons to pre-plan
surgical procedures in a digital environment. Orthoview offers access to a large
library of digital templates and ensures pre-operative planning is accurate,
reproducible and effective.

6. Optos plc (5.4%)
Development and sale of ophthalmic equipment. In 1999, Optos gained US
regulatory approval to distribute its wide field retinal imaging machine. This
machine pictures more of the retina than its competitors and does not cause the
patient any discomfort.

7. ID Data plc (4.4%)
ID Data is the UK's leading independent card and card solutions
company, with its headquarters in Corby, Northamptonshire. ID Data provides a
wide range of solutions to the leading financial service organisations,
telephony and retail clients. The company has a proven track record in providing
complete end-to-end card based solutions to a wide range of customers, both in
the UK and overseas.

8. Citel Technologies Limited (3.9%)
The company has developed integrated telephony and computer technology
for linking or combining the telephone to the desktop computer.

9.  Maelor plc (3.3%)
Maelor is a bio-medical company developing healthcare products in
areas of substantial unmet needs. The company utilises novel technologies that
will improve infusion fluids and off-patent medicines. It also produces medical
products and devices with innovative delivery systems which offer significant
advantages over other products.

10. Online Travel Corporation plc (3.0%)
OTC is an Internet-based travel technology and distribution business,
providing a comprehensive range of technological solutions, travel products and
ancillary travel services to ISP's, media and affinity groups and corporate
organisations.







Corporate Information

                                    
                                    Directors
                           Sir Patrick Lawrence CBE DL
                                 Raymond Abbott
                                John Andrews MBE
                                  Philip Court
                                  Antony Diment
                                  John Gregory
                                        

Company Secretary                                   Solicitors & VCTTax Adviser
Noble Group Limited                                          Martineau Johnson
76 George Street                                              St Philips House
Edinburgh                                                     St Philips Place
EH2 3BU                                                             Birmingham
Tel: 0131 225 9677                                                      B3 2PP

Registered Office                             Venture Capital Portfolio Adviser
St Philips House                                    Noble Fund Managers Limited
St Philips Place                                                   76 George St
Birmingham                                                            Edinburgh
B3 2PP                                                                  EH2 3BU
                                                                 

Auditors                                       Bankers & Loan Portfolio Manager
Scott-Moncrieff                                             Lloyds TSB Bank plc
Chartered Accountants                                                 PO Box 70
17 Melville Street                                              125 Colmore Row
Edinburgh                                                            Birmingham
EH3 7PH                                                                  B3 3RD

Registrar                                                        Company Broker
Lloyds TSB Registrars Scotland                        Charles Stanley & Co. Ltd
POBox 28448                                                      25 Luke Street
Finance House                                                            London
Orchard Brae                                                           EC2A 4AR
Edinburgh                                                    Tel: 020 7739 8200
EH4 1WQ

Company Registered Number
3157189









                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
IR FSDFMWSDSEDF